NSE filing, NSE: SYNGENE. Summary written from the filing by ALFA Finder's alert engine.
Syngene International Ltd: key numbers
- Share price
- ₹397.95
- Market cap
- ₹16,064 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 86.3×Sector 46.1×
- Promoter holding
- 52.59%+0.00% QoQ
- FII holding
- 10.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Earnings Call Transcript: Key Takeaways
Syngene reports a transitional quarter with sequential recovery but YoY declines due to the absence of the large Librela revenue stream.
Syngene International Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 833 Cr (down 9% YoY, up 13% QoQ). Operating EBITDA margin 18% on forex hedge losses. PAT before exceptionals Rs 38 Cr (down 44% YoY). Focus on integrated CRDMO and first Bayview biologics deal.
Syngene International Results Update
Syngene reported Q2 FY27 revenue of Rs 833 Crore, up 13% sequentially, with PAT of Rs 32 Crore. Release includes P&L highlights and business updates.
Syngene International Management Change
Syngene reports changes in senior management: two heads move from SMP to Non-SMP, Ajay Tandon resigns effective October 30, 2026, and CFO Deepak Jain plans to leave. The CFO is a KMP, so this is a material leadership change.
Syngene International Q2 FY27 Results: Net Profit ₹32.2 Cr, Down 52.0% YoY
Syngene International Ltd reported revenue from operations of ₹832.7 Cr (-8.6% YoY) and net profit of ₹32.2 Cr (-52.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹32.2 Cr · -52.0% YoY
Syngene International Other Announcement
Syngene International Limited has submitted the quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.
Other results update announcements
All →Fino Payments Bank Results Update
Fino Payments Bank's press release reports Q2 FY27 revenue of Rs.333.6 Crore and a H1 net loss. Loan referral disbursals surged 286% year-on-year.
Indostar Capital Finance Results Update
IndoStar reported Q2 FY27 standalone results, with disbursements up 51% YoY to ₹1,399 crore. Profit after tax rose to ₹13.1 crore and AUM reached ₹8,459 crore.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Asset Reconstruction Company (India) Results Update
ARCIL's H1FY27 release shows total income up 48% to Rs.516.4 crore and PAT up 54% to Rs.290.0 crore. Investors should view performance over a longer horizon.
Capital Small Finance Bank Results Update
Capital SFB's Q2 FY27 PAT rose 30.7% year-on-year to ₹45.61 crore, while advances grew 23.4%. Asset quality improved, with GNPA at 2.36% and NNPA at 1.12%.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.